CN112969449B - 特利加压素组合物及其用途 - Google Patents

特利加压素组合物及其用途 Download PDF

Info

Publication number
CN112969449B
CN112969449B CN201980053281.8A CN201980053281A CN112969449B CN 112969449 B CN112969449 B CN 112969449B CN 201980053281 A CN201980053281 A CN 201980053281A CN 112969449 B CN112969449 B CN 112969449B
Authority
CN
China
Prior art keywords
terlipressin
acetate
composition
amount
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980053281.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN112969449A (zh
Inventor
M·马尔姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ferring BV
Original Assignee
Ferring BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring BV filed Critical Ferring BV
Publication of CN112969449A publication Critical patent/CN112969449A/zh
Application granted granted Critical
Publication of CN112969449B publication Critical patent/CN112969449B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201980053281.8A 2018-06-15 2019-06-14 特利加压素组合物及其用途 Active CN112969449B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862685447P 2018-06-15 2018-06-15
US62/685447 2018-06-15
PCT/IB2019/055004 WO2019239386A1 (en) 2018-06-15 2019-06-14 Terlipressin compositions and uses thereof

Publications (2)

Publication Number Publication Date
CN112969449A CN112969449A (zh) 2021-06-15
CN112969449B true CN112969449B (zh) 2025-03-11

Family

ID=67742882

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980053281.8A Active CN112969449B (zh) 2018-06-15 2019-06-14 特利加压素组合物及其用途

Country Status (9)

Country Link
US (1) US11931398B2 (https=)
EP (1) EP3806823A1 (https=)
JP (2) JP7523775B2 (https=)
CN (1) CN112969449B (https=)
BR (1) BR112020025380A2 (https=)
CA (1) CA3103215A1 (https=)
MX (1) MX2020013389A (https=)
TW (1) TW202003548A (https=)
WO (1) WO2019239386A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220080023A1 (en) * 2018-12-21 2022-03-17 Arecor Limited Novel composition
KR20220011697A (ko) 2019-05-22 2022-01-28 바이오비에 아이앤씨. 테를리프레신 제형
CN114177147B (zh) * 2021-12-15 2023-05-23 福建省闽东力捷迅药业股份有限公司 一种注射用特利加压素的制备方法以及制得的注射用特利加压素
US20240156895A1 (en) * 2022-10-28 2024-05-16 Mallinckrodt Pharmaceuticals Ireland Limited Compositions for improving kidney function in patients with hepatorenal syndrome

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102440957A (zh) * 2011-12-16 2012-05-09 深圳市健元医药科技有限公司 醋酸特利加压素鼻腔喷雾剂及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5482931A (en) * 1993-06-29 1996-01-09 Ferring Ab Stabilized pharmaceutical peptide compositions
CN1244794A (zh) * 1997-11-06 2000-02-16 奥尔班公司 用于药物释放的稳定的干燥药物组合物及其制备方法
RU2415149C2 (ru) * 2006-02-10 2011-03-27 Ферринг Б.В. Пептидные соединения
CN102068685A (zh) * 2010-04-09 2011-05-25 深圳翰宇药业股份有限公司 一种特利加压素制剂及其制备方法
CN104334117A (zh) 2012-01-26 2015-02-04 恩多沙普公司 用远端和/或近端控制来输送管腔闭塞装置的系统、装置和方法
AR091902A1 (es) * 2012-07-25 2015-03-11 Hanmi Pharm Ind Co Ltd Formulacion liquida de un conjugado de insulina de accion prolongada
CN105592855A (zh) * 2013-04-26 2016-05-18 拉卓拉药物公司 用于治疗肾衰竭的组合物和方法
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
CN106188218B (zh) * 2016-07-14 2018-11-23 江苏诺泰澳赛诺生物制药股份有限公司 一种提高多肽原料药稳定性的方法
GB201721846D0 (en) 2017-12-22 2018-02-07 Arecor Ltd Novel composition
KR20220011697A (ko) 2019-05-22 2022-01-28 바이오비에 아이앤씨. 테를리프레신 제형

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102440957A (zh) * 2011-12-16 2012-05-09 深圳市健元医药科技有限公司 醋酸特利加压素鼻腔喷雾剂及其制备方法

Also Published As

Publication number Publication date
US20210161995A1 (en) 2021-06-03
JP2024086898A (ja) 2024-06-28
US11931398B2 (en) 2024-03-19
MX2020013389A (es) 2021-03-31
CN112969449A (zh) 2021-06-15
JP7523775B2 (ja) 2024-07-29
EP3806823A1 (en) 2021-04-21
WO2019239386A1 (en) 2019-12-19
JP2021527084A (ja) 2021-10-11
TW202003548A (zh) 2020-01-16
BR112020025380A2 (pt) 2021-05-18
CA3103215A1 (en) 2019-12-19

Similar Documents

Publication Publication Date Title
CN112969449B (zh) 特利加压素组合物及其用途
Dhondup et al. Acid-base and electrolyte disorders in patients with and without chronic kidney disease: an update
EP2525796B1 (en) Aqueous solution comprising 3-quinuclidinones for the treatment of hyperproliferative, autoimmune and heart disease
PH12014501988B1 (en) Pharmaceutical formulations of tnf-alpha antibodies
US12083129B2 (en) Treatment of breast cancer using combination therapies comprising an ATP competitive AKT inhibitor, a CDK4/6 inhibitor, and fulvestrant
CN103070871B (zh) 一种氟维司群的药物组合物
CN114652825A (zh) 稳定的抗体制剂及其制备方法和应用
CN110545808A (zh) 含有艾瑞布林或其药剂学上允许的盐的注射剂
US20240092936A1 (en) Methods of treating her2 positive breast cancer with tucatinib in combination with capecitabine and trastuzumab
US20250108053A1 (en) Ribociclib pharmaceutical compositions
TW202103734A (zh) 治療克隆氏症（ｃｒｏｈｎ＇ｓ ｄｉｓｅａｓｅ）的方法
US20250049802A1 (en) Combination therapies and uses for treating cancer
WO2022120791A1 (zh) 司来普伐肽的新用途
KR20220100634A (ko) 안정한 수성 항-tfpi 항체 제제
CN114727984A (zh) 治疗患有局部晚期鳞状细胞癌的患者的给药方案
CN119950703B (zh) 抗体制剂
US20250312297A1 (en) Reduction of healthcare resource utilization by patients treated with intranasally-administered metoclopramide
Silvio et al. S1109 Vedolizumab Long-Term Treatment Persistence and Safety–Results From a Multinational Extended Access Program Study
HK40075622A (en) Stable antibody preparation, and preparation method and use thereof
CN120035437A (zh) 用于治疗EGFR突变癌症的N-(1-((R)-1-丙烯酰基氮杂环庚烷-3-基)-7-氯-6-(((R)-四氢呋喃-3-基)氧基)-1H-苯并[d]咪唑-2-基)-2-甲基异烟酰胺(NX-019)
EA051220B1 (ru) Стабильный состав глюкокортикоидов
CN117257936A (zh) 一种阿达木单抗组合物
CN120813385A (zh) 通过施用配体-药物偶联体治疗卵巢癌
CN120361228A (zh) 一种葡萄糖激酶激活剂与pi3k抑制剂的组合物
CN115884783A (zh) Ghrh类似物的低剂量药物组合物及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant